BackGeneReach Biotechnology Overview

GeneReach Biotechnology Current Assets

Track GeneReach Biotechnology's current assets ($480M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$479.21M
↓ 6.17% YoYΔ $-31.53M vs prior year quarter

Peer trimmed avg / median

Loading

GeneReach Biotechnology Current Assets History

Loading

GeneReach Biotechnology vs. peers: Current Assets Comparison

Loading

GeneReach Biotechnology Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

GeneReach Biotechnology (4171.TWO) FAQ

The latest current assets for 4171.TWO is $480M as of June 2026. That compares with $510M in the prior-year period — down 6.2% year over year. Investors often review this figure alongside GeneReach Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4171.TWO's current assets moved from $510M to $480M — a 6.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneReach Biotechnology's operating scale or balance-sheet position.

A current assets figure of $480M for 4171.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4171.TWO's current assets ($480M), review year-over-year change from $510M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack GeneReach Biotechnology's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.